Drug, bio-affecting and body treating compositions inventions 03/06

20060069010 - Detoxification depot for alzheimer's disease: The invention is directed to a device that is placed inside an Alzheimer's disease (AD) patient for the purpose of extracting and accumulating neurotoxic beta-amyloid peptides (nt-bAP) from body fluids. AD is the consequence of a process in which nt-bAP aggregates to form fibrils and plaques which can cause nerve...

20060069011 - Method for treatment and repair of meniscal injuries: A method for repair of meniscal injuries comprising induction of meniscal regeneration by introducing a strongly adhesive collagen-polyethylene glycol (PEG) hydrogel to a site of injury....

20060069012 - Methods and compositions for treating plasticity in a subject: Methods and compositions for at least maintaining plasticity in a system of a subject are provided. Embodiments of the subject methods include lowering long term potentiation in said subject in a manner effective to at least maintain plasticity of a system in said subject....

20060069008 - Treatment of neurological deficits in the striatum or substanta nigra pars compacta: The present invention is directed to methods of treating neurological deficits resulting from injury or disease to the striatum or substanta nigra pars compacta of a human by administering human recombinant GDF5 to the striatum or substanta nigra pars compacta of a human in amounts effective to induce cell populations...

20060069009 - Treatment of neurological deficits in the striatum or substanta nigra pars compacta: The present invention is directed to methods of treating neurological deficits resulting from injury or disease to the striatum or substanta nigra pars compacta of a human by administering BMP7 to the striatum or substanta nigra pars compacta of a human in amounts effective to induce cell populations having the...

20060069013 - Pharmaceutical preparations comprising acid-stabilised insulin: Novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer that are capable of prolonging the action of insulin preparations are disclosed....

20060069016 - Cyclosporin alkyne analogues and their pharmaceutical uses: v

20060069014 - Inhibition of histone deacetylase as a treatment for cardiac hypertrophy: The present invention provides for methods of treating and preventing cardiac hypertrophy. Class II HDACs, which are known to participate in regulation of chromatin structure and gene expression, have been shown to have beneficial effects on cardiac hypertrophy. Surprisingly, the present invention demonstrates that HDAC inhibitors inhibit cardiac hypertrophy by...

20060069015 - Novel cyclosporin analogues and their pharmaceutical uses: e

20060069017 - Somatostatin analog and uses thereof:

20060069023 - Animal model for studying hormone signalling and method of modulating the signalling: The present invention relates generally to a method for the treatment and/or prophylaxis of conditions arising from or otherwise associated with aberrations in hormone signalling. The present invention further provides an animal model useful for screening for agents capable of agonizing or antagonizing hormone signalling. More particularly, the present invention...

20060069021 - Compositions and methods for intranasal administration of inactive analogs of pth or inactivated preparations of pth or pth analogs: Pharmaceutical compositions and methods are described comprising at inactive forms or parathyroid hormone peptide (PTH) or PTH analogs wherein the inactive forms are activated upon administration into the systemic circulation. Also described is a method of preventing local reaction to a biologically active agent, preparing a formulation comprising said biologically...

20060069019 - Crystal structure of the complex of hepatocyte growth factor beta chain with met receptor and methods of use: The disclosure provides a crystal structure of a complex of the HGF β-chain with am extracellular fragment of the Met receptor, as well as use of the crystal structure in the design, identification, and selection of ligands that modulate the Met Receptor and the interaction of HGF with the Met...

20060069022 - D-isomers of antimicrobial peptide: This invention provides D-isomers of MUC7-12-mer peptide of human saliva MUC7. The isomers have antimicrobial activity comparable to that of the L-isomers and are resistant to proteolysis. These peptides can be used as antifungal and antimicrobial agents....

20060069018 - Endogenous repair factor production promoters: It relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (PG) I2 agonist, EP2 agonist and EP4 agonist. Since prostaglandin (PG) I2 agonist, EP2 agonist or EP4 agonist has various endogenous repair factor production accelerating action, angiogenesis acceleration action and stem...

20060069029 - Exendin analog formulations: Novel formulations containing exendins, exendin agonists and/or exendin analogs are provided....

20060069027 - Inhibitors of hepatitis c virus: The present invention relates to methods that employ peptides or peptide derivatives to inhibit hepatitis C virus infection. The present invention is based in part on the discovery that E2 envelope glycoprotein of hepatitis C virus has previously undescribed domains that are important for interactions with cellular or viral proteins...

20060069020 - Kallikrein inhibitors and anti-thrombolytic agents and uses thereof: Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion...

20060069024 - Plant pr-5 proteins as mammalian therapeutic agents: Proteins of the PR-5 family having a lectin-like β barrel domain control apoptosis in yeast through receptor binding. Receptors that specifically bind to PR-5 proteins having a lectin-like β barrel domain have been found to be homologous to mammalian adiponectin receptors, and such PR-5 proteins can act as functional homologues...

20060069025 - Survivin, a protein that inhibits cellular apoptosis, and its modulation: The present invention provides the amino acid of a protein that inhibits cellular apoptosis, herein termed the Survivin protein and nucleic acid molecules that encode Survivin. Based on this disclosure, the present invention provides isolated Survivin protein, isolated Survivin encoding nucleic acid molecules, methods of isolating other members of the...

20060069028 - Therapeutic agents and methods of use thereof for the modulation of angiogenesis: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to...

20060069026 - Treatment of obesity: A method for the treatment of obesity in an animal such as a human, comprises administering to the animal an effective amount of a peptide which comprises the carboxyl-terminal sequence of a growth hormone, particularly the carboxyl-terminal sequence of human growth hormone containing amine acid residues 177-191. A pharmaceutical composition...

20060069030 - Apolipoprotein a1 mimetics and uses thereof: The present invention provides peptidomimetics derived from Apolipoprotein A-I, which is useful for beneficially influencing lipid parameters and/or plasma cholesterol levels. The invention also provides pharmaceutical compositions and methods of treatment for elevated levels of plasma cholesterol....

20060069032 - Beta-endorphin activity in cosmetics and dermatology: The subject of the invention is the use of at least one compound chosen from β-endorphin and β-endorphin-mimetic agents on the keratinocytes of the skin, for example in a cosmetic composition to enhance the barrier function of the skin, enhance its resistance to stress and in particular to pollution. It...

20060069031 - Use of gnrh agonists to support the luteal phase during infertility treatment: The present invention concerns the use of an agonist of an hypothalamic hormone for the preparation of a pharmaceutical agent to support the luteal phase during infertility treatment of female mammals and more specifically of women. According to this invention, the pharmaceutical agent is suitable to be used for supporting...

20060069034 - Antipathogenic benzamide compounds: e

20060069035 - Peptide for regulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy: The present invention relates to compositions of the polypeptide EEIIMID and one or more fibrinolytic agents selected from the group consisting of scuPA, tPA, uPA, tcuPA, streptokinase, rt-PA, alteplase, rt-PA derivatives, reteplase, lanoteplase, TNK-rt-PA, anisoylated plasminogen streptokinase complex, anistreplase, or a streptokinase derivative. The invention further relates to methods of...

20060069033 - Use of poly-amminopyrrolecarboxamides alone or in combination with a cyclodextrin in the prophylaxis and treatment of animal parasitosis: Use of distamycin, analogues and/or derivatives thereof in the manufacture of a pharmaceutical composition having activity against endoparasitosis in animals....

20060069036 - Methods of treatment of inflammation using glutathiones: Topical treatment of inflammatory skin diseases by application to affected skin areas of a composition containing glutathione. In the preferred embodiments of the invention, the glutathione is provided in a carrier at very high concentration levels, in the range of 16-70 percent by weight, more preferably 40-60 percent by weight....

20060069037 - Peptide-containing alpha-ketoamide cysteine and serine protease inhibitors: This invention relates to peptide-containing α-ketoamide inhibitors of cysteine and serine proteases, methods for making these compounds, and methods for using the same....

20060069038 - Irreversible caspase-3 inhibitors as active site probes: The present invention encompasses a compound of Formula (I) useful as caspase active site probes. These probes can be used to determine whether a caspase has been activated, in cells or in tissues of animal models of various pathologies. Furthermore, through competition based assays, these caspase active site probes can...

20060069040 - Ghb compositions: The invention provides a combination of sodium gamma-hydroxybutyrate (GHB) or a prodrug or an analog thereof, with a compound that inhibits the metabolism of the GHB or GHB analog in vivo, thus prolonging or enhancing the bioactivity thereof....

20060069041 - Novel hydrophilic analogs of 4,8-dihydrobenzodithiophene-4,8-diones as anticancer agents: The present invention discloses hydrophilic derivatives of 4,8-dihydrobenzodithiophene-4,8-diones, which are active as anticancer agents, along with pharmaceutical formulations containing the same....

20060069039 - Treatment of dyskinesia: The present invention relates to the treatment of dyskinesia with compounds of General Formula (I) such as topiramate. The compound may be topiramate or a derivative thereof. The dyskinesia may be associated with a basil ganglia-related movement disorder such as parkinsonism and may also arise as a side-effect of other...

20060069042 - Cytochrome p450 2c9 inhibitors: This invention is to provide multiple specific inhibitors of cytochrome P450 isozyme CYP2C9. These inhibitors can be derived from any combinations with the following compounds including: Tamarixetin, Formononetin, isoliquritigenin, Phloretin, luteolin, Quercitrin, quercetin, myricetin, Wongonin, Puerarin, Genistein, Nordihydroguaiaretic acid, Narigenin, Capillarisin, Chrysin, Fisefin, eriodictyol, 6-Gingerol, Isorhamneti, isoquercitrin, Morin, (+)-Taxifolin, isovitexin,...

20060069043 - Chiral separation, characterization and biological action of optically active isomers of digoxin: Disclosed herein is the method for separation of enantiomers or isomers of digoxin. These isomers are to be used in the treatment of heart failure without adverse or unneeded cardiac actions in humans. Additionally what is claimed is an isolate with less or no cardiac contractile effect but with AV...

20060069044 - Modified glycosaminoglycans, pharmaceutical compositions and methods for oral delivery thereof: This invention provides a composition comprising a depolymerized glycosaminoglycan or derivative thereof covalently linked to a bile acid. This invention also provides a pharmaceutical composition comprising a depolymerized glycosaminoglycan or derivative thereof covalently linked to a bile acid and a pharmaceutically acceptable carrier. Finally, this invention provides a method for...

20060069045 - Methods for treating familial dysautonomia: The present invention provides methods for modulating mRNA splicing in a normal or diseased cell or individual, e.g., elevating wild-type IKBKAP transcripts and the level of functional IKAP protein in an individual suffering from Familial Dysautonomia, by providing catechins, such as EGCG, to the cell or individual. The present invention...

20060069046 - Process for the production of (-)-epigallocatechin gallate: A process is provided for making (−)-epigallocatechin gallate (EGCG) by subjecting a green tea extract to chromatography on a macroporous polar resin, eluting EGCG from the resin with a polar elution solvent, optionally concentrating the eluate, optionally regenerating the resin by desorbing the remaining catechins, and optionally concentrating the desorbed...

20060069047 - Antibiotic conjugates: This invention features a compound of the following formula (I): wherein T is a transportophore, L is a bond or linker, and C is an antibiotic therapeutic agent, the transportophore is covalently bonded to the antibiotic therapeutic agent via the bond or the linker, and the transportophore is an azithromycin...

20060069048 - Novel bicyclic 9a-azalide derivatives: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the...

20060069051 - Ache antisense oligonucleotide as an anti-inflammatory agent: Disclosed is a novel use for AChE antisense oligonucleotides as anti-inflammatory agents, wherein said oligonucleotides are preferably as denoted by SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:7. Methods of treatment of inflammatory conditions, as well as fever, and particularly inflammation-associated neuropathies such as Guillain-Barré Syndrome, are described....

20060069058 - Beta-sheet breaker peptide analogs that inhibit beta-pleated sheet formation in amyloid beta-peptide: The present invention provides peptide analogs and peptide mimetics that inhibit pleated sheet formation in amyloid β-peptide, pharmaceutical compositions thereof and their therapeutic use. The inhibitory peptides possess activity as inhibitors in the formation of amyloid-like deposits and are useful in the treatment of Alzheimer's Disease....

20060069054 - Compositions and methods for the therapy and diagnosis of breast cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides....

20060069055 - Delivery of polynucleotides: The present invention concerns methods and formulations for non-parental delivery of nucleic acid molecules to cells. In particular, the present invention relates to methods and formulations that enhance the transport of poly- and oligonucleotides across biological membranes....

20060069052 - Dna vaccines that expresses mutant adp-ribosyitransferase toxins which display reduced, or are devoid of, adp-ribosyltransferase activity: The present invention provides DNA vaccines that direct the coincident expression of vaccine antigens coincidently with mutant ADP-ribosyltransferase toxins (mARTs), which display reduced, or are devoid of, ADP-ribosyltransferase activity, and methods for vaccinating animals with the same. In particular, the present invention provides DNA vaccines that direct the coincident expression...

20060069057 - Medicaments containing xenogeneic oligo- and/or polyribonucleotides: The invention relates to medicaments that contain xenogenic oligo- or/and polyribonucleotides as the effective component. The invention further relates to the use of said xenogenic oligo- or/and polyribonucleotides for treating herpesviridae infections and skin tumors....

20060069053 - Methods and compositions for enhancing cartilage repair: The invention relates to methods of enhancing repair of a cartilage and/or inducing formation of a cartilage by administering a cell, which expresses a factor of the T-box family, which includes inter-alia the brachyury. In another embodiment, the invention relates to an engineered cell, which is transfected with a vector...

20060069050 - Methods and compositions for mediating gene silencing: The present invention provides methods of conducting RNAi using siRNAs that are sequentially administered as single-stranded oligonucleotides. The siRNAs can be canonical or have non-canonical ends. The compositions and methods of the invention can bypass activation of interferon pathways and yet still efficiently and specifically activate RNAi/gene silencing. In another...

20060069049 - Methods and reagents related to foxo: The present invention relates to regulating the activity of Foxo and prevention and treatment of diseases associated with aberrant Foxo activity....

20060069056 - Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases: The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a...

20060069059 - Topical formulations for the treatment of depression with s adenosyl methionine: Disclosed herein are topical formulations for treating depression with S adenosyl methionine (SAM-e) The topical formulations contain at least 35% wt/wt of SAM-e partially dissolved in aqueous and lipophilic phases of an emulsion and the emulsion is stable from separation of phases for a period of at least 30 days...

20060069060 - Salts of decitabine: The present invention relates to salts of decitabine as well as methods for synthesizing the salts described herein. Pharmaceutical compositions and methods of using the decitabine salts are also provided, including methods of administering the salts or pharmaceutical compositions thereof to treat conditions, such as cancer and hematological disorders....

20060069061 - Compositions containing uridine and choline, and methods utilizing same: The present invention is directed to methods of improving cognitive and neurological functions and increasing synthesis and release of neurotransmitters and membrane synthesis by neural cells and brain cells, comprising administering a composition comprising a uridine and a choline....

20060069062 - Diructose anhydride-containing composition and use thereof: The present invention relates to a difructose anhydride (DFA)-containing composition and use thereof. DFA is a cyclic disaccharide in which the reducing termini of two fructose molecules bind each other to hydroxyl groups at the other nonreducing termini. According to the present invention, it has been revealed that DFA is...

20060069063 - Crosslinked polygalacturonic acid used for postsurgical tissue adhesion prevention: Disclosed is a crosslinked PGA that is obtained by crosslinking PGA polymer with a crosslinking reagent to develop a three-dimensional crosslinked PGA structure. The crosslinked PGA has good tissue antiadhesion and biocompatibility....

20060069064 - Methods for facilitating recovery of functions of endogenous or implanted or transplanted stem cells using hyaluronic acid: Hyaluronic Acid (HA) is an essential component of tissue extracellular matrices that contributes to the architecture of stem cell niches, which determine the fate of stem cells. Decreased levels of HA are found in subjects experiencing a variety of pathological conditions, as well as in subjects receiving a variety of...

20060069065 - Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or...

20060069066 - Glycogen synthase kinase-3 inhibitors: Novel compounds designed to allow interactions with binding sites of GSK-3 and hence are capable of inhibiting GSK-3 activity, via inhibition of substrate binding are disclosed. Further disclosed are pharmaceutical compositions including same and methods of using same in the treatment of GSK-3 mediated conditions....

20060069067 - Combination of an aromatase inhibitor with a bisphosphonate: The present invention provides a combination for the treatment of a disease or condition which responds to aromatase inhibition, in particular a proliferative disease, especially a malignant disease such as breast cancer or similar soft tissue endocrine-sensitive cancer, most preferably breast cancer, comprising an aromatase inhibitor and a bisphosphonate for...

20060069069 - Methods and compositions for the administration of calcium chelators, bisphosponates and/or citrate compounds and their pharmaceutical uses: A composition is provided which contains calcium chelators, bisphosphonates, and/or citrate compounds and which may be used for treating and or reducing pathological calcifications, heavy metal poisoning, the growth of Nanobacterium Calcifying Nano-Particles and calcification-induced diseases in humans and animals. The method includes administering a therapeutic composition of calcium chelators,...

20060069068 - Methods and compositions for the treatment of diseases characterized by pathological calcification: Methods and compositions are provided which contains preparations of calcium chelators, bisphosphonates, antibiotics, antimicrobial agents, cytostatic agents, calcium ATPase and pyrophosphatase pump inhibitors, calcium phosphate-crystal dissolving agents, agents effective against calcium phosphate-crystal nucleation and crystal growth, and/or a combination of supportive agents and which may be used for treating and...

20060069070 - Treatment of fibrosis using fxr ligands: The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a...

20060069071 - Treatment of dermatitis with dehydroepiandrosterone-glucocorticoid combinations: Dermatitis can be effectively treated with the combined administration of dehydroepiandrosterone (DHEA) and a glucocorticoid. Systemic, topical and prepackaged DHEA-glucocorticoid embodiments are described....

20060069074 - Genetic predictor of efficacy of anti-asthmatic agents for improving pulmonary function: The present invention relates to methods for determining and predicting the efficacy of therapeutics for the treatment of an individual with asthma based on that individual's β2-adrenergic receptor. The invention finds particular applicability to the treatment of an individual with asthma with an inhaled corticosteroid or a leukotriene receptor antagonist...

20060069073 - Medicaments for inhalation comprising steroids and an anticholinergic: The present invention relates to novel pharmaceutical compositions based on steroids and salts of an anticholinergic, processes for preparing them and their use in the treatment of respiratory complaints....

20060069072 - Method of male sexual enhancement: A method of sexual enhancement in men includes the steps of testing the blood of the man to determine the levels of free estradiol and free testosterone therein, assuring that the man's blood includes free estradiol within a first predetermined range and free testosterone within a second predetermined range, and...

20060069075 - Methods for treating dry eye: Methods of treating dry eye by administering fixed combinations of MUC-1 secretagogues, such as HETE derivatives, and anti-inflammatory steroids are disclosed....

20060069076 - Lxr/rxr-related methods and compositions: This invention provides methods for decreasing the amount of Aβ peptide produced by a neuronal cell comprising contacting the cell with an agent that, when in contact with the neuronal cell, causes activation of the cell's Liver X Receptor (LXR) and/or Retinoid X Receptor (RXR). This invention also provides for...

20060069078 - Management of ophthalmologic disorders, including macular degeneration: A drug may be used in the preparation of a medicament for the treatment or prevention of an ophthalmologic disorder, wherein the drug inihibits, antagonizes, or short-circuits the visual cycle at a step of the visual cycle that occurs outside a disc of a rod photoreceptor cell....

20060069077 - Receptor-type kinase modulators and methods of use: The present invention provides compounds for modulating receptor kinase activity, particularly ephrin and EGFR, and methods of treating diseases mediated by receptor kinase activity utilizing the compounds and pharmaceutical compositions thereof. Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels...

20060069079 - Stable amorphous cefdinir: The present invention relates to stable amorphous 7-[2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamide]-3-vinyl-3-cephem-4-carboxylic acid (syn isomer), methods for its preparation, and pharmaceutical compositions comprising stable amorphous 7-[2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamide]-3-vinyl-3-cephem-4-carboxylic acid (syn isomer)....

20060069080 - Combinations of substituted azetidinones and cb1 antagonists: The present invention provides compositions, therapeutic combinations and methods including: (a) at least one selective CB1 antagonist; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity, metabolic syndrome and lowering plasma levels of sterols or 5α-stanols....

20060069081 - Carbapenem antibacterials with gram-negative activity and processes for their preparation: The present invention provides β-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of...

20060069082 - Novel substituted thiophenecarboxamides, their preparation and their use as medicaments: e

20060069083 - Pesticidal dibenzo(hetero)azepine derivatives: and Ra, Rb, Rc, Rd, Re′ Rf, Rf′ G, and p are as defined in the description; m is 0, 1, 2, 3 or 4; n is 0, 1, 2, 3 or 4; or the enantiomers or diastereomers, salts or esters thereof for combatting insects, arachnids, or nematodes, methods for...

20060069084 - Methods of inhibiting kinases: The present invention provides methods of inhibiting JAK involving the use of a group of compounds based either upon a 2-amino-6-carba-disubstituted pyrazine scaffold or a 2-amino-6-carba-disubstituted pyridine scaffold. The invention also provides methods of treating JAK-associated disease states....

20060069085 - Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones: e

20060069086 - Methods for regulating neurotransmitter systems by inducing counteradaptations: The present invention relates to methods for regulating neurotransmitter systems by inducing a counteradaptation response. According to one embodiment of the invention, a method for regulating a neurotransmitter includes the step of repeatedly administering a ligand for a receptor in the neurotransmitter system, with a ratio of administration half-life to...

20060069087 - Histamine-3 receptor antagonists: as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound...

20060069088 - Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors: which are used to modulate the CCR-2 chemokine receptor to prevent or treat inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis; and pharmaceutical compositions comprising these compounds and the use...

20060069089 - Fungicides: Fungicidal compositions of the general formula (1): wherein one of W, X, Y and Z is N and the others are CR8; R8 is H, halo, C1-4 alkyl, C1-4 alkoxy or halo(C1-4)alkyl, provided that when X is CH, Z is N, R is NHNH2, R1 is phenyl and R2 is...

20060069090 - Triazine compounds: aryl, or heteroaryl; each of R2, R4, and R5, independently, is Rc, halogen, nitro, nitroso, cyano, azide, isothionitro, SRc, or ORc; R3 is Rc, alkenyl, alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, ORc, OC(O)Rc, SO2Rc, S(O)Rc, S(O2)NRcRd, SRc, NRcRd, NRcCORd, NRcC(O)ORd, NRcC(O)NRcRd, NRcSO2, CORc, C(O)ORc, or C(O)NRcRd; n is 0, 1, 2,...

20060069091 - Oxazinones and methods for their use and synthesis: The invention pertains, at least in part, to new intermediates and synthetic methods for the stereospecific synthesis of oxazinone compounds, which are useful, for example, as antibiotics. The invention also pertains to novel olefinic oxazinone compounds, methods for their synthesis, and methods of using these compounds for the synthesis of...

20060069094 - Compositions and methods for treating cognitive disorders: Methods and pharmaceutical compositions relating to selective antagonists of the 5-HT6 receptor and 5-HT2A receptor useful for the treatment of cognitive disorders are presented....

20060069092 - Pharmaceutical compositions for the treatment of diseases related to neurotrophines: The present invention refers to pharmaceutical preparations including as active compounds 3-aza-bicyclo[3.2.1]octane derivatives of general formula (I) and/or their dimers of general formula (II) and (III) acting as agonists of human neurotrophines. Therefore, such compounds of formula (I), (II) and (III) are useful for treatment of diseases in which the...

20060069093 - Substituted 2h-1,3-benzoxazin-4(3h)-ones: Substituted benzoxazin-4(3H)-ones are provided which are useful for treating thrombosis and for reducing the likelihood and/or severity of a secondary ischemic event in a patient....

20060069095 - Azole derivatives: their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, are disclosed. Also disclosed are methods of preparation of the above-mentioned compounds, pharmaceutical compositions and salts and esters thereof containing them, as well as the use of the above-mentioned compounds in the treatment, control or prevention of illnesses such as cancer....

20060069096 - Pyrazolo[3,4-e]benzoxazoles for the treatment of glaucoma: Pyrazolo[3,4-e]benzoxazoles and analogues thereof for lowering intraocular pressure and treating glaucoma are disclosed....

20060069097 - Pyradazine compounds as gsk-3 inhibitors: The present invention relates generally to inhibitors of the kinases, such as GSK3, and more particularly to fused pyradazine compounds and methods of their use....

20060069098 - Bicyclic compound: wherein symbol “A” represents a saturated heterocyclic group, a 5-membered heteroaromatic group having two heteroatoms in the ring, a group represented by the formula A1 (R2, R3, and R4 represent hydrogen atom, hydroxyl group, etc.), etc., B represents a group represented by the formula B1 (R11 represents hydrogen atom, hydroxyl...

20060069099 - Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases: wherein variables Ra, R1, R2, R3, R4, A1, A4, L, Q, X and subscript n as described herein. The subject compounds are useful for treatment of inflammatory and immune conditions and diseases. Compositions and methods of treatment using the subject compounds are also provided. For example, the subject methods are...

20060069100 - Variously substituted derivatives of guanidine, and their use as medicines with anti-diabetes and/or anti-obesity activity: Formula (I) compounds are described where the groups are as identified in the text, and their use as medicines, particularly as anti-diabetes, serum glucose-lowering and anti-obesity agents. Said medicines are useful for the prophylaxis and treatment of diabetes, particularly type 2 diabetes, and its complications, syndrome X, the various forms...

20060069101 - Prodrugs of protein tyrosine kinase inhibitors: Novel compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as oncologic and immunologic disorders....

20060069102 - Novel heterocyclic nf-kb inhibitors: v

20060069103 - 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases:

20060069104 - Neurotrophic factor production accelerator: wherein R1 is lower alkyl, aryl, ar(lower)alkoxy, or a heterocyclic group, and the above groups may be substituted with halogen, R2 is a hydrogen atom or lower alkyl, R3 is cyclo(lower)alkyl, aryl or ar(lower)alkyl, and the above groups may be substituted with halogen, A is —CO—, —SO2— or lower alkylene,...

20060069105 - Protein tyrosine kinase inhibitors: e

20060069106 - Tetrahydroquinazolin-4(3h)-one-related and tetrahydropyrido[2,3-d]pyrimidin-4(3h)-one-related compounds, compositions and methods for their use: wherein variables A1, A2, A3, A4, R1, R2, R3, R4, Q and L are as described herein. The subject compounds are useful for treatment of inflammatory and immune conditions and diseases. Compositions and methods of treatment using the subject compounds are also provided. For example, the subject methods are useful...

20060069107 - Method of treating behavioral disorders: The present invention provides a method of treating behavioral disorders such as attention deficit hyperactivity disorder, comprising administering an effective amount of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine or a pharmaceutically acceptable salt thereof to a patient in need thereof and the like....

20060069108 - Use of (r)-penciclovir triphosphate for the manufacture of a medicament for the treatment of viral diseases: A method of treatment of: i) HIV-1 infections in mammals, including humans; or ii) HBV infections in mammals, including humans; which method comprises the administration to the human in need of such treatment, an effective amount of the (R)-enantiomer of the triphosphate of a compound of formula (A) or a...

20060069109 - Therapeutic agents: A compound of the Formula: (I) (A chemical formula should be inserted here—please see paper copy enclosed herewith) Formula: (I); for use as a Tie2 receptor tyrosine kinase inhibitor in a warm-blooded animal such as man....

20060069110 - Substituted heterocyclic compounds and methods of use: The present invention relates to pyridines, pyrimidines and derivatives thereof, and pharmaceutically acceptable salts thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult...

20060069111 - Compounds and methods for promoting smoking cessation: Compounds and methods for promoting smoking cessation. The compounds may be used to treat a variety of other conditions and disease states....

20060069112 - 4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the cholesterin-ester transfer protein: Hetero-tetrahydroquinolines can be prepared either by condensing correspondingly substituted hetero-tetrahydroquinoline aldehydes with the desired substituent or by reducing the corresponding keto-substituted hetero-tetrahydroquinolines, followed by introduction of the desired substituent by customary methods. The hetero-tetrahydroquinolines are suitable for use as active compounds in medicaments, in particular in medicaments for treating artheriosclerosis...

20060069113 - Analgesic compositions containing buprenorphine: An analgesic composition in parenteral unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising an amount of buprenorphine which is less than the clinical dose required to achieve pain relief and an amount of naloxone such that the ratio by weight of buprenorphine...

20060069114 - Liquid pharmaceutical formulations of palonosetron: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments....

20060069115 - Use of pde4 inhibitors as adjunct therapy for psychiatric disorders: The use of a PDE4 inhibitor in conjunction with psychotherapy provides enhanced therapeutic results in the treatment of psychiatric disorders including, for example, specific phobias, panic disorders, anxiety disorders including posttraumatic stress disorders, and obsessive-compulsive disorder....

20060069116 - 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes: The present invention is directed to 3-amino-4-phenylbutanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also...

20060069118 - Crystalline forms of a factor xa inhibitor: The instant invention provides crystalline forms of 1-(3-chlorophenyl)-7-oxo-6-[4-(2-oxo-1 (2H)pyridinyl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide and its solvates thereof; processes for the production of such crystalline forms; pharmaceutical compositions comprising such crystalline forms; and methods of treating thromboembolic disorders with such crystalline forms or such pharmaceutical compositions....

20060069119 - Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones: e

20060069117 - Imidazopyridine derivatives, preparation method and pharmaceutical compositions containing same:

20060069120 - Novel piperidine derivaties as modulators of chemokine receptor ccr5: Compounds of formula (I): wherein R1, R2, R3, R4, R5, A and X are as defined herein; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal)....

20060069121 - (arylamidoanilino)nitroethylene compounds: or a pharmaceutically acceptable salt or N-oxide thereof, wherein A, Q, Y, R1, R2, and R5 are defined herein, are useful in the treatment of tumors and cancers such as mastocytosis/mast cell leukemia, gastrointestinal stromal tumors (GIST), germ cell tumors, small cell lung carcinoma (SCLC), sinonasal natural killer/T-cell lymphoma, testicular...

20060069122 - Chemokine-binding heterocyclic compound salts, and methods of use thereof: The present invention relates to chemokine-binding heterocyclic compound salts, methods of use thereof, and methods for preparing the same....

20060069123 - Substituted dipiperidine ccr2 antagonists: e

20060069124 - Use of mdl-100,907 for treatment of allergic and eosinophil mediated diseases: Methods of modulating eosinophil migration, chemotaxis or generation, in vitro, ex vivo, and in vivo are provided. Methods include contacting eosinophils with an amount of 5-HT2A receptor agonist or antagonist sufficient to modulate eosinophil migration, chemotaxis or generation....

20060069125 - Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride: The present invention provides a crystalline donepezil maleate, which is used as an intermediate in the preparation of donepezil hydrochloride. Also provided are novel processes for producing same in substantially pure form and a process for producing pharmaceutically pure amorphous donepezil hydrochloride therefrom....

20060069126 - Pharmaceutically active isoindoline derivatives: Isoindolin-1-one and Isoindoline-1,3-dione substituted in the 2-position with a 2,6-dioxo-3-hydroxypiperidin-5-yl group, which may be further substituted in the 5-position with alkyl or halogeno, and in the 4-position with alkyl or a nitrogen-containing group are inhibitors of, and thus useful in the treatment of disease states mediated by, TNFα. A typical...

20060069127 - Imidazolo-related compounds, compositions and methods for their use: wherein variables R0, R1, R2, R3, R4, Q, L and subscript n are as described herein. The subject compounds are useful for treatment of infammatory and immune conditions and diseases. Compositions and methods of treatment using the subject compounds are also provided. For example, the subject methods are useful for...

20060069128 - N-ureidoalkyl-piperidines as modulators of chemokine receptor activity: The present application describes N-ureidoalkyl piperidines as modulators of chemokine receptors, or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases....

20060069129 - Chemokine receptor binding heterocyclic compounds: The present invention is drawn to novel antiviral compounds, pharmaceutical compositions and their use. More specifically this invention is drawn to derivatives of monocyclic polyamines which have activity in standard tests against HIV- or FIV-infected cells as well as other biological activity related to binding of ligands to chemokine receptors...

20060069130 - Novel crystals: Obtaining the crystal of 4,6-dimethyl-4′-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]nicotinanilide having excellent activity of inhibiting Ca2+ release-activated Ca2+ channel and suppressing IL-2 production to find that the compound includes the presence of two types of polymorphic crystals and that any of the crystals is preferable as a raw material for producing pharmaceutical compositions....

20060069131 - Novel complexes of fatty acid esters of polyhydroxyalkanes and pyridine carboxy derivatives: The present invention relates to novel combinations of fatty acid derivatives and pyridine carboxy derivatives, including fatty acid esters with glycerol and 3-carboxy pyridine derivatives such as niacinamide. Such combinations have surprisingly shown antiviral and anti-microbial activity and the use for the treatment of inflammatory conditions and infections is disclosed...

20060069132 - Azolecarboxamide herbicides: wherein J, R1a, R1b, R1c, R2a, R2b, R3, R4, R5, T, U, W, Y and Z are as defined in the disclosure; and an effective amount of another herbicide or herbicide safener. Also disclosed is a method for selectively controlling undesired vegetation in a crop that involves contacting the locus...

20060069133 - Body weight gain inhibitor: The invention provides a pharmaceutical agent containing a compound having an angiotensin II antagonistic activity, a prodrug thereof or a salt thereof, which shows superior effect for the suppression of body weight gain. In addition, the present invention provides such a pharmaceutical agent as does not increase body weights of...

20060069135 - Benzimidazole derivatives and their use for modulating the gaba-a receptor complex: e

20060069134 - Process for producing optically active alpha-substituted cysteine or salt thereof, intermediate therefor, and process for producing the same: The present invention provides a simple, practical, and industrially advantageous process for producing an optically active α-substituted cysteine or a salt thereof from inexpensive and readily available materials. The present invention provides a process for producing an optically active α-substituted cysteine or a salt thereof by converting a cysteine derivative...

20060069136 - Use of epothilones in the treatment of bone metastasis: The present invention relates to the use of Epothilones in the treatment of bone metastases and bone tumors or cancers, more particularly in treating, preventing or alleviating bone metastasis in a cancer patient....

20060069137 - Novel process for ezetimibe intermediate: The invention provides a process for preparing intermediate of ezetimibe, which shows hypocholesterolemic activity. Thus 3-[5-(4-fluorophenyl)-1,5-dioxopentyl]4-phenyl-2-oxazolidinone is reduced with (−)-DIP chloride to obtain 3-[(5S)-5-(4-fluorophenyl)-5-hydroxy-1-oxopentyl]4-phenyl-2-oxazolidinone....

20060069139 - Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof: Disclosed are novel NO-donating compounds, designed such that when NO is released from the compound a residue which is a naturally occurring metabolite is formed, and thus a development of tolerance to the compounds upon repetitive administration is prevented or decreased. Also disclosed are methods of preparing such NO-donating compounds,...

20060069138 - Thiazole-based nitric oxide donors having alkyl substuent(s) and uses thereof: Disclosed are novel NO-donating compounds, designed such that when NO is released from the compound a residue which is a naturally occurring metabolite is formed, and thus a development of tolerance to the compounds upon repetitive administration is prevented or decreased. Also disclosed are methods of preparing such NO-donating compounds,...

20060069141 - Preparation of olmesartan medoxomil: The present invention provides a process for preparing olmesartan medoxomil....

20060069140 - Pyrazolone compounds and thrombopoietin receptor activator: A preventive, therapeutic or improving agent for diseases against which activation of the thrombopoietin receptor is effective or a platelet increasing agent, which contains a thrombopoietin receptor activator represented by the formula (1): wherein A is a C?2-14#191 aryl group, B is a hydrogen atom, a C?1-6#191 alkyl group, a...

20060069144 - 4-(condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists: where the variables have the meaning defined in the specification are agonists of alpha2 adrenergic receptors. Several compounds of the disclosure are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors. Additionally some of the claimed compounds have no or only minimal cardivascular and/or...

20060069143 - 4-(heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists: where the variables have the meaning defined in the specification are agonists of alpha2 adrenergic receptors. Several compounds of the disclosure are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors. Additionally some of the claimed compounds have no or only minimal cardivascular and/or...

20060069142 - Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same: where the variables have the meaning defined in the specification are used to activate alpha2 adrenergic receptors. The compounds of Formula 1 are incorporated in pharmaceutical compositions and are used as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment...

20060069145 - Tricycles, their manufacture and use as pharmaceutical agents: e

20060069146 - Imidazole derivatives modulating the sodium channels:

20060069147 - Sulfonamides, sulfamates and sulfamides as gamma-secretase inhibitors:

20060069148 - Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment: Fluoro substituted cycloalkanoindole derivatives are antagonists of prostaglandins, and as such are useful for the treatment of prostaglandin mediated diseases....

20060069149 - Thiadibenzoazulene derivatives for the treatment of inflammatory diseases: The present invention relates to (a) novel 1-thiadibenzoazulene derivatives of the formula (I), (b) to their pharmacologically acceptable esters, salts and solvates, (c) to processes and intermediates for the preparation thereof, (d) to a process for preparing pharmaceutical formulations for the treatment of inflammatory diseases and conditions and (e) to...

20060069150 - Processes for preparation of crystalline mycophenolate sodium: Provided are crystalline mycophenolate sodium forms and processes for their preparation....

20060069151 - Novel use of lycopene: Lycopene can be used in the primary prevention and incidence risk reduction of non-cancerous symptoms and/or pathologies (i.e., the prophylactic supplementation of the healthy subjects), in the treatment or the coadjuvant treatment of non-can-cerous symptoms and/or pathologies (i.e. the supplementation as therapy or accompanying a running therapy) and in the...

20060069152 - Crystalline mycophenolate sodium: Provided are crystalline mycophenolate sodium forms and processes for their preparation....

20060069153 - Use of a class of antiviral compounds for production of an agent for the treatment or prevention of a viral infection in the respiratory tract: The invention discloses a use of dithiocarbamate compounds having the structural formula R1R2NCS2H, in which R1 and R2, independently of each other, represent a straight or branched C1-C4 alkyl, or, with the nitrogen atom, form an aliphatic ring with 4 to 6 C atoms, in which R1, R2, or the...

20060069154 - Enzyme activated self-immolative n-substituted nitrogen mustard prodrugs: wherein: RN is independently C1-7alkyl; X1 is independently —I, —Br, or —Cl; X2 is independently —I, —Br, or —Cl; the group —N(CH2CH2X1)(CH2CH2X2) is independently attached at the 2-position or at the 4-position; each RG is independently —H or an ester substituent; n is independently an integer from 0 to 4;...

20060069155 - Method for reducing exacerbations associated with copd: This invention relates to a method for reducing the incidences and/or the severity of exacerbations of COPD by administering a phosphodiesterase 4 (PDE4) inhibitor....

20060069156 - Acylated aminopropanediols and analogues and therapeutic uses thereof: The invention relates to novel acylated aminopropanediols and the nitrogen and sulfur analogues thereof, pharmaceutical compositions comprising same, therapeutic uses thereof, in particular for the treatment of cerebral ischemia. The invention also provides a method of preparing said derivatives....

20060069157 - Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as huntington's disease, by sodium butyrate chemotherapy: A method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as Huntington's disease, includes administering a histone deacetylase (HDAC) inhibitor in a subject in need thereof. The HDAC inhibitor includes sodium butyrate....

20060069158 - Lipoxin compounds and their use in treating cell proliferative disorders: Compounds having the active site of natural lipoxins, but a longer tissue half-life are disclosed. In particular, 15-epi-lipoxins and their use in ameliorating undesired cell proliferation, which characterizes diseases such as cancer, are also disclosed....

20060069159 - Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation: This invention is directed to methods and compositions which impede the development and progression of diseases associated with subclinical inflammation. Subclinical inflammation is commonly associated with atherosclerotic cardiovascular disease, coronary disease or cerebrovascular disease. The methods and compositions of the invention are also particularly suited to providing therapy for subclinical...

20060069160 - Composition for treating bacterial, viral, fungal diseases, inflammation and pain: The present invention is directed to compositions and methods of treating bacterial, viral, fungal diseases; inflammation or inflammatory-related disorders; pain; and skin conditions. The composition comprises an organic solvent extract, which is prepared by the method comprising the steps of: (a) mixing methionine with water, (b) adding an aqueous hypochlorite...

20060069161 - Methods and reagents for the treatment of metabolic disorders: The invention features compositions, methods, and kits for the treatment of metabolic disorders such as diabetes and obesity....

20060069162 - Transparent eye drops containing latanoprost: An object of the present invention is to provide better formulations of a latanoprost ophthalmic solution. The present invention provides a clear ophthalmic solution comprising latanoprost as an active ingredient and benzalkonium chloride as a preservative wherein white turbidity due to a change of formulation is prevented by at least...

20060069163 - Method for treating alzheimer's disease: The present invention provides a method for treating or preventing the onset of Alzheimer's Disease comprising administering to a mammal in need thereof an Alzheimer's Disease-preventing or treating amount of a plasma-triglyceride level-lowering agent. Optionally, the plasma-triglyceride level-lowering agent can be co-administered with a cholesterol level-lowering agent....

20060069164 - Process for preparing terbinafine by using platinum as catalyst: A process for the preparation of terbinafine, comprising the reaction of a compound of formula (II), or a salt thereof, wherein X is a leaving group, with tert-butylacetylene, in the presence of a platinum catalyst....

20060069165 - Treating morning hypertension by lowering morning blood pressure levels with propranolol: This invention relates to a method and kit having a composition for reducing morning blood pressure levels (for treating morning hypertension). Pursuant to this method, a therapeutic amount of β-adrenergic-blocking agent is administered nightly to a person that suffers from blood pressure level attacks such that the blocking agent is...

20060069166 - Laser treatment of cutaneous vascular lesions: Methods for treating maladies such as cutaneous vascular lesions. A patient in need of vascular lesion treatment is identified. A hyperosmotic agent is administered to a region adjacent the lesion. Blood flow velocity is slowed within the region using the hyperosmotic agent, and the lesion is exposed to laser radiation....

20060069167 - 1-chloro-2,4-dinitrobenzene gel compositions and methods for using the same: Gel compositions that contain 1-dichloro-2,4-dinitrobenzene (DNCB) are provided. Embodiments of the subject gel compositions include DNCB, an organic solvent and a viscosity agent, wherein the organic solvent and viscosity agent are inert with respect to the DNCB. Also provided are methods for using the subject compositions and kits for use...

20060069168 - Vascular embolization material: This invention provides an embolization material used for blocking a blood vessel in vivo for stopping the blood flow. The most suitable embolization material has a water swelling ratio of 30% or more, is degradable in a phosphate buffered saline, is formed as virtually spherical particles, and is preferably composed...

20060058219 - Aminobutyramide conjugate and a pharmaceutical composition for treatment of neuronal disorders: where R is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine blood brain barrier (BBB) peptide, membrane translocating protein, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin,...

20060058221 - Baclofen conjugate and a pharmaceutical composition for treatment of neuronal disorders: where R1 is p-chlorophenyl, R is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine blood brain barrier (BBB) peptide, membrane translocating protein, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin,...

20060058217 - Compositions and methods for treatment of ovarian cancer: Compositions and methods for treatment of ovarian cancer are described. The compositions comprise antalamin, a compound that increases cytotoxic T-cell lytic activity at tumor sites. Methods of treatment for ovarian cancer are based on the administration of antalarmin to increase cytotoxic T-cell lytic activity or anti-tumor activity, which leads to...

20060058222 - Endocannabinoid conjugate and a pharmaceutical composition for treatment of neuronal disorders: A compound provided by the present invention includes an endocannabinoid, endocannabinoid derivative, or endocannabinoid analog moiety covalently bonded to a biologically active peptide. One example of an inventive compound described is a conjugate of an endocannabinoid, endocannabinoid derivative, or endocannabinoid analog moiety covalently coupled to an opioid peptide, such as...

20060058220 - Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same: Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are, disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of...

20060058224 - Methods of treating obesity with combination therapeutics: Compositions and methods of treating obesity or obesity-related condition, including reducing body-weight, improving-diabetic parameters, metabolic syndrome. liver steatosis, and/or hypertension with a combination of CNTF or a CNTF-related molecule and a second agent which is a therapeutic molecule useful in the treatment of obesity, type II diabetes, or other obesity-related...

20060058218 - Solid phase conjugation of complexing agents and targeting moieties: There is provided a technique for conjugating one or more complexing agents with a targeting moiety, such as natural amino acids, unnatural amino acids, peptides, peptide nucleic acids, nucleotides, and analogs and derivatives thereof. The one or more complexing agents are conjugated at one or more free amino groups of...

20060058223 - Taj in neuronal function: The invention provides methods of treating diseases, disorders, injuries, or conditions involving modulating neurite outgrowth and/or survival, including CNS disorders, stroke, or spinal injury, by administration of a TAJ antagonist....

20060058225 - Used of inhibitors of phospholipase a2 for the treatment, prevention or diagnosis of neural inflammatory or demyelinating disease: The present invention provides methods of preventing and treating neural inflammatory or demyelinating disease, such as multiple sclerosis, via an inhibition of the activity or expression of phospholipase A2. The invention further relates to methods of identifying phospholipase A2 inhibitors and their use thereof for the prevention and/or treatment of...

20060058230 - Analogs of parathyroid hormone and pth-related protein as bone anabolic agents: The invention provides novel parathyroid hormone analogs and parathyroid hormones-related protein analogs. The invention also provides methods of using these analogs to treat osteoporosis, promote the formation of bone, and inhibit bone loss....

20060058231 - Bmp-7 variants with improved properties: The invention relates to variants of BMP-7 with improved properties and methods for their use....

20060058228 - Colon tumor specific binding peptides: Phage display was used to screen peptide libraries that distinguish between well-differentiated (HCT116) and poorly-differentiated colon carcinoma cells (HT29). The screening protocol used selection and subtraction on intact, viable cells, resulting in phage libraries exhibiting high binding selectivity for the poorly-differentiated HT29 cells. A nine amino acid, disulfide-constrained peptide (RPM)...

20060058236 - Endogenously-formed conjugate of albumin: A conjugate formed in vivo and comprised of endogenous albumin and an amine-containing compound, such as a protein or a drug, is described. The conjugate is formed by in vivo cleavage of a polymer-dithiobenzyl-therapeutic agent conjugate to form an albumin-dithiobenzyl-therapeutic agent conjugate. The dithiol moiety of the albumin-therapeutic agent conjugate...

20060058238 - Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same: The present invention provides methods and compositions designed for treating a subject suffering from skin conditions, disorders or diseases. The compositions include fetal skin cell proteins obtained from fetal skin cells after induced cell lysis....

20060058226 - Gd3-mimetic peptides: GD3-Mimetic peptides which contain an amino acid sequence represented by any of SEQ ID NOS: 1 to 4 or an amino acid sequence derived therefrom by substitution, deletion, addition, or insertion of one or more amino acid residues and attaining specific binding to an anti-GD3 antibody; and medicinal compositions containing...

20060058227 - Hedgehog-related prophylaxis, therapy and diagnosis of gi tract carcinogenesis: The present invention is based on the key roles played by Hedgehog proteins in the regulation of homeostasis of the adult intestinal epithelium. Ihh is expressed in the adult mammalian colon and provides a lineage-instructive signal and regulates colonic epithelial morphogenesis in a compartmental fashion. Loss of Ihh expression precedes...

20060058235 - Long lasting synthetic glucagon like peptide (glp-1): Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified...

20060058232 - Methods of treating cancer using a modified endostatin protein: The present invention provides methods of treating an angiogenesis-related disease of a subject using a therapeutically effective amount of a modified endostatin protein. In particular, the methods encompass treating an angiogenesis-related disease of a subject using a combination of the modified endostatin, and a known cancer therapy agent such as...

20060058237 - P49/strap is a novel protein involved in gene regulation and cell proliferation: The invention provides isolated p49/STRAP protein, and isolated nucleic acids encoding a p49/STRAP protein. The inventors have discovered a new protein, named p49/STRAP that is expressed in cardiac tissue and other tissues in mammals. The p49/STRAP protein binds to serum response factor (SRF) and regulates transcription of SRF-responsive genes in...

20060058229 - Peptides and methods for cell death regulation: The present invention provides novel peptides, nucleic acids, compounds, compositions and methods for regulating apoptosis, and screening methods for identifying same. Regulation of apoptosis is mediated via IAPi-derived proteins, peptide fragments thereof, and nucleic acids encoding same, stimulating/accelerating or downmodulating/suppressing apoptosis. For stimulation/acceleration of apoptosis, the IAPi-derived proteins or peptide...

20060058233 - Prevention and treatment of synucleinopathic and amyloidogenic disease: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic...

20060058239 - Use of the insulin-like-growth factor i isoform mgf for the treatment of neurological disorders: The invention relates to the treatment of neurological disorders with the Insulin-like Growth Factor I (IGF-I) isoform known as mechano growth factor (MGF)....

20060058234 - Vegf traps and therapeutic uses thereof: Nucleic acid molecules and multimeric proteins capable of binding vascular endothelial growth factor (VEGF). VEGF traps are disclosed which are therapeutically useful for treating VEGF-associated conditions and diseases, and are specifically designed for local administration to specific organs, tissues, and/or cells....

20060058240 - Peptides and compounds that bind to a receptor: Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide...

20060058241 - Methods of treating disorders having a component of mercury toxicity: The present invention relates to methods of lowering the level of mercury in a subject, methods of lowering the level of mercury in a child diagnosed with autism and methods of assessing the risk of whether a child is susceptible of developing autism....

20060058242 - Dipeptide derivatives: e

20060058243 - Methods and compositions for treating diabetes mellitis: Methods for modulating diabetes, impaired glucose tolerance, gestational diabetes and glucose resistance in a mammal, particularly a human. In one embodiment the method comprises administering a gallotannin composition to a mammal in need of the same. The gallotannin composition comprises one or more select hydrolysable gallotannins. In another embodiment the...

20060058244 - New pyrazole derivatives and diabetic medicine containing them: The present invention provides pyrazole-O-glycoside derivatives represented by the following formulae, used as a diabetic medicine....

20060058245 - Methods for treatment of thiol-containing compound deficient conditions: Methods for therapy of cystic fibrosis and other conditions are provided. The methods comprise one or more agents capable of increasing thiol-containing compound transport via a transporter system (i.e. ABC transporters such as MDR-1 or MRP-2) in cells. Other embodiments include the use of agents to modulate transport of thiol-containing...

20060058246 - Macrolide compounds endowed with antiinflammatory activity: Macrolide compounds endowed with antiinflammatory activity are described, and more particularly macrolide derivatives lacking cladinose in position 3, with antiinflammatory activity, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing them as active ingredient....

20060058247 - Methods and compositions for treating cystic fibrosis: The present invention provides methods of using improved macrolide compositions in the treatment of cystic fibrosis. The macrolide compounds of Formulas 1-21 described herein may be used alone or in a cotherapeutic regimen with other agents that are active against cystic fibrosis. The present invention also provides compositions and methods...

20060058248 - Processes for the preparation of 6-11 bicyclic erythromycin derivatives: The present invention relates to processes and intermediates for the preparation of 6-11 bicyclic erythromycin derivatives. In particular, the present invention relates to processes and intermediates for the preparation of a compound of formula (IX-c):...

20060058249 - Efficient nucleic acid encapsulation into medium sized liposomes: A method for preparing liposomes containing at least one nucleic acid encapsulated therein comprising the following steps: (A) mixing a gel or a liquid containing gel particles with aqueous medium Z1 to directly form the liposomes containing the at least one nucleic acid encapsulated therein; (B)(i) mixing a gel or...

20060058250 - Methods of treating proliferative skin diseases using carbazole derivatives: The present invention relates to a method of treating a proliferative skin disease, comprising administering a therapeutically effective amount of a trk inhibitor....

20060058258 - Gene transcription and ionizing radiation: methods and compositions: The present invention provides a DNA molecule comprising a radiation responsive enhancer-promoter operatively linked to an encoding region that encodes at least one polypeptide. An encoding region can comprise a single encoding sequence for a polypeptide or two or more encoding sequences encoding DNA binding, activation or repression domains of...

20060058254 - Immunostimulatory sequence oligonucleotides and methods of using the same: The invention provides immunomodulatory polynucleotides and methods for immunomodulation of individuals using the immunomodulatory polynucleotides....

20060058257 - Influencing angiogenesis using cd66a: The invention relates to a method of influencing angiogenesis by administering a of a compound in a pharmaceutically compatible carrier selected from the group consisting of (i) CD66a, a CD66a variant, CD66a fragments or CD66a-derived glycostructures, or CD66a ligands, or (ii) of anti-CD66a specific antibodies and anti-sense oligonucleotides....

20060058252 - Methods and materials for treating human papillomavirus infections: The invention provides methods and materials related to treating HPV infections (e.g., HPV infections of cutaneous and mucosal epithelial cells) and HPV-associated conditions (e.g., cervical dysplasia, HPV-associated cervical carcinomas, oral mucosal papilloma cancers, laryngeal papilloma cancers)....

20060058251 - Methods for treating and preventing infectious disease: Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity, and B cell proliferation are disclosed. The sequences are also useful as a synthetic adjuvant....

20060058253 - Methods to reprogram splice site selection in pre-messenger rnas: The present invention relates to a method of modulating splice site selection, splicing and alternative, the method comprising the step of hybridizing an oligonucleotide-protein conjugate to a target pre-mRNA molecule in a cell or cell extract, wherein the oligonucleotide-protein conjugate comprises an oligonucleotide moiety which comprises at least two distinct...

20060058256 - Oligoribonucleotides for the treatment of degenerative skin conditions by rna interference: The invention relates to oligoribonucleotides, which are capable of inducing breakdown of the mRNA enzymes that break down connective tissue, and to pharmaceutical and cosmetic compositions, which are provided for topical application and which contain the oligoribonucleotides. The compositions are particularly suited for treating degenerative skin disorders....

20060058255 - Rnai-based therapeutics for allergic rhinitis and asthma: The present invention provides compositions comprising one or more RNAi agents (e.g., siRNAs, shRNAs, or RNAi vectors) for the treatment of conditions and diseases mediated by (e.g., featuring IgE-mediated hypersensitivity), as well as systems for identifying RNAi agents effective for this purpose. The compositions are suitable for the treatment of...

20060058259 - Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine: A method for treatment of HBV and HIV infections comprising administering the compound or salt of formula Ig...

20060058260 - Combination therapy with gemcitabine and zd6126: The present invention relates to a method for the production of a vascular damaging effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer involving a solid tumour, which comprises the administration of ZD6126...

20060058261 - Chitin derivatives for hyperlipidemia: The preferred embodiments relate to chitin derivatives for prevention or treatment of hyperlipidemia, such as hypercholesterolemia and the resultant atherosclerosis in a mammal. The preferred embodiments are useful for reducing serum cholesterol, and/or cholesteryl ester, triglycerides, phospholipids and fatty acids in a mammal....

20060058262 - New injectable formulations containing progesterone: The present invention relates to injectable progesterone formulations and processes for their preparation....

20060058263 - Heat pasturized liquids containing glucosamine: The disclosure provides methods of making heat-pasteurized liquids, such as beverages, that contain glucosamine, wherein glucosamine is present in the beverage during the pasteurization process. The disclosure also provides liquids, such as beverages, made by these methods, as well as methods of using the glucosamine supplemented liquids, for example to...

20060058264 - Opioid receptor ligands and methods for their preparation: that are opioid receptor ligands. The invention also provides pharmaceutical compositions comprising such compounds as well as methods for treating diseases associated with opioid receptor function by administering such compounds to a mammal in need of treatment. The invention also provides an improved method for isolating intermediate materials useful for...

20060058266 - Chemically modified oligonucleotides: This invention relates composition and methods for making and using chemically modified oligonucleotides agents for inhibiting gene expression....

20060058265 - Topical antiviral formulations: The present invention relates to formulations of nucleotide reverse transcriptase inhibitors (NRTIs), preferably [2-(6-Amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid (tenofovir, PMPA), or a physiologically functional derivative thereof, suitable for topical application and their use in the prevention of HIV infections....

20060058267 - Pharmaceutical compositions comprising a nos inhibitor: This invention relates to methods of treating neurodegenerative diseases and inhibiting neurological damage, comprising administering to a patient in need of such treatment an N-NOS inhibitor in combination with a GABA-A receptor modulator....

20060058268 - Compounds and methods for treating diabetic vascular diseases: i

20060058269 - Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation: A method for inhibiting and/or ameliorating the occurrence of diseases in a human subject whereby a subject is administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative. In some embodiments, the administration of analogs or derivatives of carotenoids may inhibit and/or ameliorate...

20060058270 - Ruthenium anticancer complexes: Ruthenium (II) compounds of formula (I) are useful in the treatment and/or prevention of cancer, wherein formula (I) is:...

20060058271 - Methods for screening, studying, and treating dissorders with a component of mercurial toxicity: The present invention is related to a method, system or process for screening, studying and treating disorders which have a component of mercurial including: autism, autism spectrum disorders, ADD, ADHD, mental retardation, Asperger's syndrome, childhood psychoses, stammering, stuttering, tics, repetitive movements, eating disorders, sleep disorders, enuresis, disturbances of emotion, developmental...

20060058272 - Pharmaceutical composition for use as a contraceptive: A pharmaceutical composition comprises, as a first active agent, 6β,7β;15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone (drospirenone) in an amount corresponding to a daily dosage, on administration of the composition, of from about 2 mg to about 4 mg, and, as a second active agent, 17α-ethinylestradiol (ethinylestradiol) in an amount corresponding to a daily dosage of...

20060058273 - Mastitis treatment: A pharmaceutical composition for intramammary administration to a nonhuman mammal comprising an antibacterial agent and prednisolone, wherein the composition comprises at least 20 mg of prednisolone, and its use for the treatment of clinical mastitis....

20060058274 - Use of an aldosterone receptor antagonist to improve cognitive function: Aldosterone receptor antagonists for the prevention and treatment of cognitive dysfunction are disclosed....

20060058275 -